Sirolimus inhibits lymphangiogenesis in rat renal allografts, a novel mechanism to prevent chronic kidney allograft injury

Transplant International

Volumn 26, Issue 2, 2013, Pages 195-205

  Palin, Niina K ^a   Savikko, Johanna ^a   Koskinen, Petri K ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

chronic kidney allograft injury; lymphangiogenesis; sirolimus; VEGF C; VEGFR 3

Indexed keywords

CREATININE; CYCLOSPORIN A; RAPAMYCIN; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC ALLOGRAFT DAMAGE INDEX; CHRONIC KIDNEY ALLOGRAFT INJURY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; HISTOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LYMPH VESSEL; LYMPHANGIOGENESIS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RATING SCALE; RENAL GRAFT DYSFUNCTION; UPREGULATION;

ANIMALS; CHRONIC DISEASE; CYCLOSPORINE; GRAFT REJECTION; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; LYMPHANGIOGENESIS; MALE; MICROSCOPY, FLUORESCENCE; RATS; RATS, WISTAR; RENAL INSUFFICIENCY; SIROLIMUS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84872612047     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12005     Document Type: Article

References (28)

1. Kerjaschki D, Regele HM, Moosberger I, et al,. Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates. J Am Soc Nephrol 2004; 15: 603.
2. Stuht S, Gwinner W, Franz I, et al,. Lymphatic neoangiogenesis in human renal allografts: results from sequential protocol biopsies. Am J Transplant 2007; 7: 377.
3. Vass DG, Shrestha B, Haylor J, Hughes J, Marson L,. Inflammatory lymphangiogenesis in a rat transplant model of interstitial fibrosis and tubular atrophy. Transpl Int 2012; 25: 792.
4. Tammela T, Alitalo K,. Lymphangiogenesis: molecular mechanisms and future promise. Cell 2010; 140: 460.
5. Cursiefen C, Chen L, Borges LP, et al,. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004; 113: 1040.
6. Baluk P, Tammela T, Ator E, et al,. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest 2005; 115: 247.
7. Jeltsch M, Kaipainen A, Joukov V, et al,. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 1997; 276: 1423.
8. Makinen T, Jussila L, Veikkola T, et al,. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 2001; 7: 199.
9. Forster R, Davalos-Misslitz AC, Rot A,. CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol 2008; 8: 362.
10. Schena FP, Pascoe MD, Alberu J, et al,. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233.
11. Guba M, von Breitenbuch P, Steinbauer M, et al,. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128.
12. Huber S, Bruns CJ, Schmid G, et al,. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int 2007; 71: 771.
13. Kobayashi S, Kishimoto T, Kamata S, Otsuka M, Miyazaki M, Ishikura H,. Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci 2007; 98: 726.
14. Savikko J, Kallio EA, Taskinen E, von Willebrand E,. The effect of acute rejection and cyclosporin A-treatment on induction of platelet-derived growth factor and its receptors during the development of chronic rat renal allograft rejection. Transplantation 2002; 73: 506.
15. Isoniemi H, Taskinen E, Hayry P,. Histological chronic allograft damage index accurately predicts chronic renal allograft rejection. Transplantation 1994; 58: 1195.
16. Sis B, Mengel M, Haas M, et al,. Banff '09 Meeting Report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464.
17. Drayton DL, Liao S, Mounzer RH, Ruddle NH,. Lymphoid organ development: from ontogeny to neogenesis. Nat Immunol 2006; 7: 344.
18. Mobley JE, O'Dell RM,. The role of lymphatics in renal transplantation. Renal lymphatic regeneration. J Surg Res 1967; 7: 231.
19. Nykanen AI, Sandelin H, Krebs R, et al,. Targeting lymphatic vessel activation and CCL21 production by vascular endothelial growth factor receptor-3 inhibition has novel immunomodulatory and antiarteriosclerotic effects in cardiac allografts. Circulation 2010; 121: 1413.
20. Partanen TA, Arola J, Saaristo A, et al,. VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J 2000; 14: 2087.
21. Tammela T, Zarkada G, Wallgard E, et al,. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008; 454: 656.
22. Paavonen K, Puolakkainen P, Jussila L, Jahkola T, Alitalo K,. Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am J Pathol 2000; 156: 1499.
23. Kulkarni RM, Greenberg JM, Akeson AL,. NFATc1 regulates lymphatic endothelial development. Mech Dev 2009; 126: 350.
24. Watson CJ, Firth J, Williams PF, et al,. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant 2005; 5: 2496.
25. Lebranchu Y, Thierry A, Toupance O, et al,. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 2009; 9: 1115.
26. Guba M, Pratschke J, Hugo C, et al,. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial. Transplantation 2010; 90: 175.
27. Pontrelli P, Rossini M, Infante B, et al,. Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy. Transplantation 2008; 85: 125.
28. Servais A, Meas-Yedid V, Toupance O, et al,. Interstitial fibrosis quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimus. Am J Transplant 2009; 9: 2552.